CNMD · Conmed Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $337.93M | $342.35M | $321.26M | - | $316.70M | $332.10M | $312.27M | - | $304.58M |
| Cost of Revenue | - | $171.81M | $154.03M | $143.50M | - | $137.71M | $148.37M | $140.31M | - | $136.52M |
| Gross Profit | - | $166.12M | $188.32M | $177.75M | - | $179.00M | $183.73M | $171.97M | - | $168.06M |
| R&D | - | $13.90M | $14.14M | $12.95M | - | $13.56M | $14.10M | $13.59M | - | $12.46M |
| SG&A | - | $140.34M | $136.02M | $148.85M | - | $99.73M | $122.52M | $123.36M | - | $125.30M |
| Total Operating Expenses | - | $154.24M | $150.16M | $161.79M | - | $113.29M | $136.62M | $136.95M | - | $137.76M |
| D&A | - | - | - | $4.24M | - | - | - | $4.05M | - | - |
| Operating Income | - | $11.88M | $38.16M | $15.96M | - | $65.71M | $47.11M | $35.01M | - | $30.30M |
| Interest Expense | - | $7.61M | $7.82M | $8.29M | - | $9.25M | $9.59M | $9.59M | - | $10.02M |
| Income Tax | - | $1.41M | $8.50M | $1.64M | - | $7.47M | $7.54M | $5.71M | - | $4.44M |
| Net Income | - | $2.86M | $21.42M | $6.04M | - | $48.98M | $29.98M | $19.71M | - | $15.84M |
| EPS - Basic | - | $0.09 | $0.69 | $0.19 | - | $1.59 | $0.97 | $0.64 | - | $0.52 |
| EPS - Diluted | - | $0.09 | $0.69 | $0.19 | - | $1.57 | $0.96 | $0.63 | - | $0.50 |
Balance Sheet
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $40.82M | $38.93M | $33.94M | $35.48M | $24.46M | $38.47M | $28.87M | $33.85M | $24.30M | $30.50M |
| Accounts Receivable | $247.83M | $224.94M | $234.15M | $221.14M | $237.73M | $231.23M | $239.22M | $241.46M | $242.28M | $230.20M |
| Inventory | $355.54M | $364.36M | $362.25M | $354.68M | $346.72M | $342.55M | $322.36M | $322.30M | $318.32M | $325.82M |
| Accounts Payable | $93.65M | $107.09M | $101.05M | $95.73M | $102.25M | $104.57M | $101.29M | $101.64M | $88.22M | $81.87M |
| Current Assets | $672.86M | $662.16M | $657.78M | $639.00M | $640.01M | $641.00M | $623.83M | $635.72M | $615.65M | $625.65M |
| Total Assets | $2.33B | $2.32B | $2.33B | $2.30B | $2.31B | $2.32B | $2.29B | $2.31B | $2.30B | $2.33B |
| Current Liabilities | $315.04M | $314.70M | $294.84M | $283.15M | $278.13M | $282.31M | $266.41M | $291.40M | $310.73M | $376.32M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.29B | $1.31B | $1.33B | $1.32B | $1.34B | $1.38B | $1.40B | $1.45B | $1.47B | $1.53B |
| Stockholders' Equity | $1.03B | $1.01B | $1.00B | $977.64M | $962.68M | $932.90M | $881.83M | $854.66M | $834.22M | $796.21M |
| Retained Earnings | $588.77M | $572.03M | $575.36M | $560.13M | $560.28M | $532.70M | $489.89M | $466.08M | $452.53M | $425.61M |
Cash Flow
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | $41.53M | - | - | - | $29.12M | - | - |
| Investing Cash Flow | - | - | - | ($2.93M) | - | - | - | ($2.04M) | - | - |
| Financing Cash Flow | - | - | - | ($28.40M) | - | - | - | ($17.01M) | - | - |
| CapEx | - | - | - | $3.78M | - | - | - | $2.04M | - | - |
| Free Cash Flow | - | - | - | $37.76M | - | - | - | $27.09M | - | - |
Ratios
| Metric | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 49.2% | 55.0% | 55.3% | - | 56.5% | 55.3% | 55.1% | - | 55.2% |
| Operating margin | - | 3.5% | 11.1% | 5.0% | - | 20.7% | 14.2% | 11.2% | - | 9.9% |
| EBITDA margin | - | - | - | 6.3% | - | - | - | 12.5% | - | - |
| Net margin | - | 0.8% | 6.3% | 1.9% | - | 15.5% | 9.0% | 6.3% | - | 5.2% |
| Free cash flow margin | - | - | - | 11.8% | - | - | - | 8.7% | - | - |
| FCF / Net income | - | - | - | 6.25 | - | - | - | 1.37 | - | - |
| R&D / Revenue | - | 4.1% | 4.1% | 4.0% | - | 4.3% | 4.2% | 4.4% | - | 4.1% |
| SG&A / Revenue | - | 41.5% | 39.7% | 46.3% | - | 31.5% | 36.9% | 39.5% | - | 41.1% |
| Effective tax rate | - | 33.1% | 28.4% | 21.3% | - | 13.2% | 20.1% | 22.5% | - | 21.9% |
| Return on assets | - | 0.1% | 0.9% | 0.3% | - | 2.1% | 1.3% | 0.9% | - | 0.7% |
| Return on equity | - | 0.3% | 2.1% | 0.6% | - | 5.3% | 3.4% | 2.3% | - | 2.0% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.14 | 2.10 | 2.23 | 2.26 | 2.30 | 2.27 | 2.34 | 2.18 | 1.98 | 1.66 |
| Quick ratio | 1.01 | 0.95 | 1.00 | 1.00 | 1.05 | 1.06 | 1.13 | 1.08 | 0.96 | 0.80 |
| Cash ratio | 0.13 | 0.12 | 0.12 | 0.13 | 0.09 | 0.14 | 0.11 | 0.12 | 0.08 | 0.08 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | 1.6x | 4.9x | 1.9x | - | 7.1x | 4.9x | 3.6x | - | 3.0x |
| Equity multiplier | 2.25 | 2.30 | 2.32 | 2.35 | 2.40 | 2.48 | 2.59 | 2.70 | 2.76 | 2.92 |
| Liabilities / Assets | 0.56 | 0.57 | 0.57 | 0.57 | 0.58 | 0.60 | 0.61 | 0.63 | 0.64 | 0.66 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.15 | 0.15 | 0.14 | - | 0.14 | 0.15 | 0.14 | - | 0.13 |
| Inventory turnover | - | 0.47 | 0.43 | 0.40 | - | 0.40 | 0.46 | 0.44 | - | 0.42 |
| Days sales outstanding | - | 243d | 250d | 251d | - | 266d | 263d | 282d | - | 276d |
| Days inventory outstanding | - | 774d | 858d | 902d | - | 908d | 793d | 838d | - | 871d |
| Days payable outstanding | - | 228d | 239d | 243d | - | 277d | 249d | 264d | - | 219d |
| Cash conversion cycle | - | 790d | 869d | 910d | - | 897d | 807d | 856d | - | 928d |
| Valuation | ||||||||||
| P / E | - | 522.6x | 75.5x | 317.8x | - | 45.8x | 72.2x | 127.1x | - | 201.7x |
| P / B | - | 1.4x | 1.6x | 1.9x | - | 2.4x | 2.4x | 2.9x | - | 4.0x |
| P / S | - | 4.3x | 4.7x | 5.9x | - | 7.1x | 6.5x | 8.0x | - | 10.5x |
| EV / EBITDA | - | - | - | 91.4x | - | - | - | 63.2x | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 6.7% | 3.1% | 2.9% | - | 4.0% | 4.5% | 5.7% | - | 10.7% |
| Revenue CAGR (3y) | - | 7.1% | 7.3% | 9.9% | - | 8.4% | 9.2% | 10.3% | - | 8.6% |
| Revenue CAGR (5y) | - | 7.3% | 16.8% | 8.5% | - | 6.3% | 6.9% | 7.4% | - | 8.5% |
| Gross profit growth (YoY) | - | -7.2% | 2.5% | 3.4% | - | 6.5% | 7.6% | 10.7% | - | 10.8% |
| Operating income growth (YoY) | - | -81.9% | -19.0% | -54.4% | - | 116.9% | 71.8% | 175.7% | - | 25.0% |
| Net income growth (YoY) | - | -94.2% | -28.5% | -69.4% | - | 209.3% | 118.3% | 983.5% | - | -65.7% |
| EPS growth (YoY) | - | -94.3% | -28.1% | -69.8% | - | 214.0% | 123.3% | 950.0% | - | -66.2% |
| EPS CAGR (3y) | - | -60.7% | - | -26.1% | - | 49.5% | 32.8% | 26.7% | - | 29.5% |
| EPS CAGR (5y) | - | -17.1% | - | -1.0% | - | 46.8% | 38.3% | 73.6% | - | 20.1% |
| FCF growth (YoY) | - | - | - | 39.4% | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | 111.3% | - | - | - | - | - | - |
| Book value growth (YoY) | 7.3% | 8.1% | 13.7% | 14.4% | 15.4% | 17.2% | 13.0% | 13.6% | 11.9% | 11.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$1.32B totalGeneral Surgery$789.74M · 59.9%
Orthopedic Surgery$529.12M · 40.1%
Geographic
$1.37B totalUS$774.59M · 56.3%
EMEA$264.65M · 19.3%
Asia Pacific$208.72M · 15.2%
Americasexcludingthe United States$126.76M · 9.2%
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing CONMED Corp against the 5 most active filers in the same SIC group.
Dividends
$0.40/share trailing 12 months · -50.0% YoY
| Ex-date | Per share |
|---|---|
| Sep 15, 2025 | $0.2000 |
| Jun 13, 2025 | $0.2000 |
| Mar 14, 2025 | $0.2000 |
| Dec 20, 2024 | $0.2000 |
| Sep 16, 2024 | $0.2000 |
| Jun 14, 2024 | $0.2000 |
| Mar 14, 2024 | $0.2000 |
| Dec 15, 2023 | $0.2000 |
| Sep 14, 2023 | $0.2000 |
| Jun 14, 2023 | $0.2000 |
| Mar 14, 2023 | $0.2000 |
| Dec 15, 2022 | $0.2000 |
| Sep 14, 2022 | $0.2000 |
| Jun 14, 2022 | $0.2000 |
| Mar 14, 2022 | $0.2000 |
| Dec 14, 2021 | $0.2000 |
| Sep 14, 2021 | $0.2000 |
| Jun 14, 2021 | $0.2000 |
| Mar 12, 2021 | $0.2000 |
| Dec 14, 2020 | $0.2000 |
| Sep 14, 2020 | $0.2000 |
| Jun 12, 2020 | $0.2000 |
| Mar 13, 2020 | $0.2000 |
| Dec 12, 2019 | $0.2000 |